Interleukin-2 secretion by transduced and unselected BDL-2 lymphoma results in increased survival in mice with previously established disseminated disease

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 2, 1996, Pages 155-164

  Orchard, Paul J ^a,d   Katsanis, Emmanuel ^a   Boyer, Michael ^a,b   May, Chad ^a,c   McIvor, R Scott ^a   Blazar, Bruce R ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Mayo Memorial Building ^*  (United States)

Author keywords

BDL 2; fibroblast; gene therapy; IL 2; lymphoma; retrovirus; tumor

Indexed keywords

INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER RESEARCH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; EXPRESSION VECTOR; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0029941014     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.155     Document Type: Article

References (40)

1. Chakravarty PK, H Fuji, MM Abu-hadid, S-C Hsu and AK Sood. Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression; potential therapeutic implications. Cancer Immunol Immunother 1992;35:347.
2. Colombo MP, A Modesti, G Parmiani and G Form. Local cytokine availibility elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk Cancer Res. 1992;52:4853.
3. Gansbacher B, FM Rosenthal and K Zier, Retroviral vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest 1993;11:345.
4. Gansbacher B, K Zier, B Daniels, K Cronin, R Bannerji and E Gilboa Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217.
5. Gansbacher B, R Bannerji, B Daniels, K Zier, K Cronin and E Gilboa Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990,50:7820.
6. Patel PM, CL Flemming, SJ Russell, SA Eccles and MKL Collins. Cytokine gene transfer as a therapeutic strategy. J Immunother. 1993;14.310.
7. Porgador A, B Gansbacher, R Bannerji, E Tzehoval, E Gilboa, M Feldman and L Eisenbach. Anti-metastatic vaccination of tumor-beanng mice with IL-2-gene-inserted tumor cells. Int J Cancer. 1993;53:471.
8. Rosenthal FM, K Cronin, R Bannerji, DW Golde and B Gansbacher. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-garnma cDNAs. Blood 1994,83:1289.
9. Hock H, M Dorsch, U Kunzendorf, K Uberla, Z Qin, T Diamantstein and T Blankenstein. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant Cancer Res 1993;53:714.
10. Watanabe Y, K Kuribayashi, S Miyatake, K Nishhara, E Nakayama, T Taniyama and T Sakata. Exogenous expression of mouse interferon g cDNA in mouse neuroblastoma C1300 cells results in reduced tumongenicity and augmented anti-tumor immunity. Proc Nalt Acad Sci USA 1989;86.9456.
11. Vieweg J, FM Rosenthal, R Bannerji, WD Heston, WR Fair, B Gansbacher and E Gilboa. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994;54:1760.
12. Connor J, R Bannerji, S Saito, W Heston, W Fair and E Gilboa Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells J Exp Med 1993;177:1127.
13. Yannelli JR, C Hyatt, S Johnson, P Hwa and SA Rosenberg. Characterization of human tumor lines transduced with the cDNA encoding either tumor necrosis factor-alpha (TNF-alpha) or interleukin-2 (IL-2). J Immunol Methods 1993;161:77.
14. Gansbacher B, K Zier, K Cronin, PA Hantzopoulos, B Bouchard, A Houghton, E Gilboa and D Golde. Retroviral gene transfer induced constitutive expression of interleukin- 2 or interferon-gamma in irradiated human melanoma cells. Blood 1992;80:2817.
15. Pardoll DM Genetically engineered tumor vaccines. Ann N Y Acad Sci. 1993;12.301
16. Dranoff G, E Jaffee, A Lazenby, P Golumbek, H Levitsky, K Brose, V Jackson, H Hamada, D Pardoll and RC Mulligan. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993,90:3539.
17. Sanda MG, SR Ayyagari, EM Jaffee, JI Epstein, SL C lift, LK Cohen, G Dranoff, DM Pardoll, RC Mulligan and JW Simons. Demonstration of a rational strategy for human prostate cancer gene therapy. Journal of Urology 1994;151:622.
18. Jaffee EM, G Dranoff, LK Cohen, KM Hauda, S Clift, FF Marshall, RC Mulligan and DM Pardoll. High efficiency gene transfer into primary human tumor explants without cell selection Cancer Res. 1993;53:2221.
19. Forai G, M Giovarelli, F Cavallo, M Consalvo, A Allione, A Modesti, P Musiani and MP Colombo. Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. [Review]. J Immunother 1993;14:253.
20. Golumbek PT, R Azhari, EM Jaffee, HI Levitsky, A Lazenby, K Leong and DM Pardoll. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993;53:5841
21. Sencer SF, ML Rich, E Katsanis, AC Ochoa and PM Anderson Anti-tumor vaccine adjuvant effects of IL -2 liposomes in mice immunized against MCA-102 sarcoma. Eur Cytokine Netw. 1991;2 311.
22. Zwiebel JA, N Su, A MacPherson, T Davis and JO Ojeifo. The gene therapy of cancer: transgenic immunotherapy. [Review]. Seminars in Hematology 1993;30:119.
23. Tsai SC, B Gansbacher, L Tait, FR Miller and GH Heppner. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst. 1993;85:546.
24. Tepper RI and JJ Mule. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5:153.
25. Felsher DW, KA Denis, D Weiss, DT Ando and J Braun. A murine model for B-cell lymphomagenesis in immunocompromised hosts: cmyc rearranged B-cell lines with a premalignant phenotype. Cancer Res. 1990;50:7042.
26. Miller AD and C Buttimore. Redesign of retroviral packaging lines to avoid recombination leading to helper virus production. Mol Cell Biol. 1986;6:2895.
27. Danos O and RC Mulligan. Safe and effective generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 1988,85:6460.
28. Katsanis E, PJ Orchard, MA Bausero, KB Gorden, RS Mclvor and BR Blazar Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retropentoneal tumors. J Immunother Emphasis Tumor Immunol 1994;15:81.
29. Katsanis E, MA Bausero, AC Ochoa, CM Loeffler, BR Blazar, AS Leonard and PM Anderson. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. Cancer Immunol Immunother. 1991,34:74.
30. Dialynas DP, ZS Quan and WK A. Characterization of murine T cell surface designated L3T4, identified by monoclonal antibody GKl 5: Similarity of L3T4 to human Leu/T4 molecule. J Immunol, 1983;131:2445.
31. Sarmiento M, AL Glasebrook and FW Fitch. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell mediated cytolysis in the absence of complement. J Immunol 1980;125:2665.
32. Culver KW. Clinical applications of gene therapy for cancer. Clinical Chemistry 1994;40:510.
33. Porgador A, E Tzehoval, A Katz, E Vadai, M Revel, M Feldman and L Eisenbach. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679.
34. Porgador A, R Bannerji, Y Watanabe, M Feldman, E Gilboa and L Eisenbach. Antimetastatic vaccination oftumor-bearing mice with two types of IFN- gamma gene-inserted tumor cells. J Immunol 1993;150:1458
35. Saito S, R Bannerji, B Gansbacher, FM Rosenthal, P Romanenko, WDW Heston, WR Fair and E Gilboa. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994;54:3516.
36. Fakhrai H, DL Shawler, R Gjerset, RK Naviaux, J Koziol, I Royston and RE Sobel. Cytokine gene therapy with interleukin-2-transduced fibroblasts - effects of il-2 dose on anti-tumor immunity. Hum Gene Ther 1995;6:591.
37. Kim TS and EP Cohen. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells. Journal of Immunotherapy with Emphasis on Tumor Immunology 1994;16:24.
38. Kim TS, SJ Russell, MK Collins and EP Cohen. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int J Cancer 1993;55:865.
39. Visseren MJW, M Koot, EIH van der Voort, LA Gravestein, HJ Schoenmakers, WM Kast, M Zijlstra and CJM Melief. Production of Interleukrn-2by EL4 tumor cells induces natural killer cell- and T-cell mediated immunity. J Immunother 1994;15:119.
40. Bannerji R, C Arroyo, C Cordon-Cardo and E Gilboa The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994;152:2324